Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:BSX
- CUSIP: 10113710
- Web: www.bostonscientific.com
Capitalization:- Market Cap: $37.04 billion
- Outstanding Shares: 1,369,401,000
Average Prices:- 50 Day Moving Avg: $27.74
- 200 Day Moving Avg: $25.82
- 52 Week Range: $19.67 - $28.51
P/E:- Trailing P/E Ratio: 86.70
- Foreward P/E Ratio: 19.46
- P/E Growth: 2.23
Sales & Book Value:- Annual Revenue: $8.58 billion
- Price / Sales: 4.32
- Book Value: $5.15 per share
- Price / Book: 5.25
Profitability:- EBIDTA: $2.22 billion
- Net Margins: 5.07%
- Return on Equity: 23.45%
- Return on Assets: 8.68%
Debt:- Debt-to-Equity Ratio: 0.78%
- Current Ratio: 0.87%
- Quick Ratio: 0.59%
Misc:- Average Volume: 6.39 million shs.
- Beta: 1.1
- Short Ratio: 1.48
Frequently Asked Questions for Boston Scientific Corporation (NYSE:BSX)
What is Boston Scientific Corporation's stock symbol?
Boston Scientific Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
How were Boston Scientific Corporation's earnings last quarter?
Boston Scientific Corporation (NYSE:BSX) posted its quarterly earnings data on Thursday, July, 27th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.45% and a net margin of 5.07%. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.27 EPS. View Boston Scientific Corporation's Earnings History.
When will Boston Scientific Corporation make its next earnings announcement?
What guidance has Boston Scientific Corporation issued on next quarter's earnings?
Boston Scientific Corporation updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $1.23-1.27 for the period, compared to the Thomson Reuters consensus estimate of $1.25. The company issued revenue guidance of $8.89-8.99 billion, compared to the consensus revenue estimate of $8.87 billion.Boston Scientific Corporation also updated its Q3 guidance to $0.29-0.31 EPS.
Where is Boston Scientific Corporation's stock going? Where will Boston Scientific Corporation's stock price be in 2017?
21 brokerages have issued twelve-month target prices for Boston Scientific Corporation's shares. Their forecasts range from $25.00 to $33.00. On average, they anticipate Boston Scientific Corporation's stock price to reach $29.91 in the next year. View Analyst Ratings for Boston Scientific Corporation.
What are analysts saying about Boston Scientific Corporation stock?
Here are some recent quotes from research analysts about Boston Scientific Corporation stock:
- 1. According to Zacks Investment Research, "Over the past one month, Boston Scientific was trading below the Zacks categorized broader Medical Products industry. Adverse foreign exchange continues to pose challenges for Boston Scientific. We are concerned with the company’s recall of one of its prime products, Lotus range of heart devices. Also dull defibrillator sale within core CRM continues to remain a drag for the overall growth. The woes of challenging economy and competitive landscape continue to weigh the stock. However, on the positive side, the company is leaving no stone unturned to strengthen its core businesses and invest in innovations and global markets. The company recently received CE mark for its Vercise Gevia DBS System which is expected to boost its European business. The increased top line guidance for 2017 also buoys optimism." (7/11/2017)
- 2. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)
- 3. Northland Securities analysts commented, "The implications for Edwards now are a longer runway without BSX truly being on the market, potential questions arising about product design / reliability of the Lotus Valve. More importantly, Edwards now has a chance to pick up incremental share in Europe. We remain strong buyers of EW." (2/23/2017)
Who are some of Boston Scientific Corporation's key competitors?
Some companies that are related to Boston Scientific Corporation include Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Koninklijke Philips N.V. (PHG), Intuitive Surgical (ISRG), Illumina (ILMN), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), Hologic (HOLX), ResMed (RMD), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX) and Quidel Corporation (QDEL).
Who are Boston Scientific Corporation's key executives?
Boston Scientific Corporation's management team includes the folowing people:
- Michael F. Mahoney, Chairman of the Board, President, Chief Executive Officer
- Daniel J. Brennan, Chief Financial Officer, Executive Vice President
- Timothy A. Pratt, Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
- Supratim Bose, Executive Vice President; President, Asia-Pacific, Middle East and Africa
- Keith D. Dawkins M.D., Global Chief Medical Officer, Executive Vice President
- Joseph M. Fitzgerald, Executive Vice President; President - Rhythm Management
- Edward F. Mackey, Executive Vice President - Operations
- Ian T. Meredith AM, Executive Vice President, Global Chief Medical Officer
- Michael P. Phalen, Executive Vice President; President - MedSurg
- Wendy Carruthers, Senior Vice President - Human Resources
Who owns Boston Scientific Corporation stock?
Boston Scientific Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bollard Group LLC (2.46%), Diamond Hill Capital Management Inc. (0.22%), APG Asset Management N.V. (0.17%), Tavio Capital LLC (0.11%), Gateway Investment Advisers LLC (0.09%) and Atalanta Sosnoff Capital LLC (0.09%). Company insiders that own Boston Scientific Corporation stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Ernest Mario, Jeffrey B Mirviss, John Bradley Sorenson, John E Abele, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Michael F Mahoney, Michael P Phalen and Timothy A Pratt. View Institutional Ownership Trends for Boston Scientific Corporation.
Who sold Boston Scientific Corporation stock? Who is selling Boston Scientific Corporation stock?
Boston Scientific Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bollard Group LLC, APG Asset Management N.V., Diamond Hill Capital Management Inc., Great West Life Assurance Co. Can, PGGM Investments, Tributary Capital Management LLC, Atalanta Sosnoff Capital LLC and Exxonmobil Investment Management Inc. TX. Company insiders that have sold Boston Scientific Corporation stock in the last year include Daniel J Brennan, David A Pierce, John Bradley Sorenson, Keith D Dawkins, Kevin J Ballinger, Michael F Mahoney, Michael P Phalen and Timothy A Pratt. View Insider Buying and Selling for Boston Scientific Corporation.
Who bought Boston Scientific Corporation stock? Who is buying Boston Scientific Corporation stock?
Boston Scientific Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Vontobel Asset Management Inc., Barometer Capital Management Inc., Russell Investments Group Ltd., ING Groep NV, Mn Services Vermogensbeheer B.V., Lockheed Martin Investment Management Co., Moody Lynn & Lieberson LLC and Tavio Capital LLC. Company insiders that have bought Boston Scientific Corporation stock in the last two years include Charles J Dockendorff and John E Abele. View Insider Buying and Selling for Boston Scientific Corporation.
How do I buy Boston Scientific Corporation stock?
Shares of Boston Scientific Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Boston Scientific Corporation's stock price today?
One share of Boston Scientific Corporation stock can currently be purchased for approximately $27.05.
MarketBeat Community Rating for Boston Scientific Corporation (NYSE BSX)MarketBeat's community ratings are surveys of what our community members think about Boston Scientific Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Boston Scientific Corporation (NYSE:BSX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Hold Ratings, 15 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.71) |
| Consensus Price Target: | $29.91 (10.56% upside) |
Analysts' Ratings History for Boston Scientific Corporation (NYSE:BSX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | Cowen and Company | Reiterated Rating | Outperform | $31.00 | Low |  |
| 7/12/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | $31.00 | Low | |
| 6/28/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight | $27.00 -> $31.00 | Low | |
| 6/28/2017 | Stifel Nicolaus | Boost Price Target | Hold | $30.00 -> $32.00 | Low | |
| 6/28/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $28.00 | Low | |
| 6/28/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Hold | | Low | |
| 6/28/2017 | Barclays PLC | Boost Price Target | Overweight -> Overweight | $30.00 -> $31.00 | Low | |
| 6/22/2017 | Needham & Company LLC | Boost Price Target | Buy | $30.00 -> $32.00 | Low | |
| 6/21/2017 | BMO Capital Markets | Reiterated Rating | Buy | $30.00 | Low | |
| 6/16/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $29.50 -> $31.00 | Low | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral -> Neutral | $28.00 | Low | |
| 4/28/2017 | Evercore ISI | Boost Price Target | Outperform | $26.50 -> $28.50 | Low | |
| 4/12/2017 | Guggenheim | Reiterated Rating | Buy | | Low | |
| 2/23/2017 | Northland Securities | Reiterated Rating | Positive | | N/A | |
| 2/5/2017 | BTIG Research | Reiterated Rating | Hold | | N/A | |
| 10/6/2016 | Citigroup Inc. | Boost Price Target | Buy | $28.00 -> $29.00 | N/A | |
| 9/1/2016 | Argus | Upgrade | Hold -> Buy | $23.82 -> $33.00 | N/A | |
| 7/29/2016 | Credit Suisse Group | Reiterated Rating | Buy | | N/A | |
| 7/29/2016 | Leerink Swann | Reiterated Rating | Buy | | N/A | |
| 7/29/2016 | Wedbush | Boost Price Target | Neutral | $23.00 -> $25.00 | N/A | |
| 7/28/2016 | Benchmark Co. | Boost Price Target | Buy | $25.00 -> $31.00 | N/A | |
| 6/21/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $26.00 | N/A | |
| 3/27/2016 | Morgan Stanley | Reiterated Rating | Overweight | $22.00 | N/A | |
| 3/25/2016 | Bank of America Corporation | Reiterated Rating | Buy | $23.00 | N/A | |
| 3/18/2016 | Longbow Research | Initiated Coverage | Buy | | N/A | |
| 3/17/2016 | Nomura | Initiated Coverage | Buy | $22.00 | N/A | |
| 3/12/2016 | Deutsche Bank AG | Reiterated Rating | Hold | | N/A | |
| 2/25/2016 | SunTrust Banks, Inc. | Initiated Coverage | Buy | $21.00 | N/A | |
| 1/4/2016 | Sterne Agee CRT | Boost Price Target | Buy | $21.00 -> $22.50 | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Boston Scientific Corporation (NYSE:BSX)Earnings History by Quarter for Boston Scientific Corporation (NYSE BSX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/27/2017 | Q2 2017 | $0.31 | $0.32 | $2.21 billion | $2.26 billion | View | N/A | |
| 4/27/2017 | Q1 2017 | $0.30 | $0.29 | $2.08 billion | $2.16 billion | View | N/A | |
| 2/2/2017 | Q416 | $0.29 | $0.30 | $2.16 billion | $2.19 billion | View | Listen | |
| 10/26/2016 | Q316 | $0.27 | $0.27 | $2.07 billion | $2.11 billion | View | Listen | |
| 7/28/2016 | Q216 | $0.27 | $0.27 | $2.05 billion | $2.13 billion | View | Listen | |
| 4/27/2016 | Q116 | $0.24 | $0.28 | $1.91 billion | $1.96 billion | View | Listen | |
| 2/4/2016 | Q415 | $0.25 | $0.26 | $2.00 billion | $1.98 billion | View | Listen | |
| 10/28/2015 | Q315 | $0.23 | $0.24 | $1.86 billion | $1.89 billion | View | Listen | |
| 7/23/2015 | Q215 | $0.21 | $0.22 | $1.83 billion | $1.84 billion | View | Listen | |
| 4/28/2015 | Q115 | $0.21 | $0.21 | $1.78 billion | $1.77 billion | View | Listen | |
| 2/4/2015 | Q414 | $0.21 | $0.22 | $1.91 billion | $1.89 billion | View | Listen | |
| 10/22/2014 | Q314 | $0.20 | $0.20 | $1.82 billion | $1.85 billion | View | Listen | |
| 7/24/2014 | Q214 | $0.20 | $0.21 | $1.87 billion | $1.87 billion | View | Listen | |
| 4/29/2014 | Q114 | $0.18 | $0.20 | $1.80 billion | $1.77 billion | View | Listen | |
| 2/4/2014 | Q4 | $0.13 | $0.21 | $1.83 billion | $1.84 billion | View | Listen | |
| 10/24/2013 | Q313 | $0.09 | $0.17 | $1.73 billion | $1.74 billion | View | Listen | |
| 7/25/2013 | Q2 2013 | $0.10 | $0.18 | $1.78 billion | $1.81 billion | View | Listen | |
| 4/25/2013 | Q1 2013 | $0.09 | $0.16 | $1.79 billion | $1.76 billion | View | Listen | |
| 1/29/2013 | Q4 2012 | $0.11 | $0.18 | $1.76 billion | $1.82 billion | View | Listen | |
| 10/18/2012 | | $0.11 | ($0.52) | | | View | N/A | |
| 7/26/2012 | | $0.08 | $0.17 | | | View | N/A | |
| 4/19/2012 | | $0.13 | $0.15 | | | View | N/A | |
| 2/2/2012 | | $0.08 | $0.07 | | | View | N/A | |
| 10/20/2011 | | $0.09 | $0.15 | | | View | N/A | |
| 7/28/2011 | | $0.08 | $0.17 | | | View | N/A | |
| 4/20/2011 | | $0.04 | $0.01 | | | View | N/A | |
| 2/1/2011 | | $0.09 | $0.15 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Boston Scientific Corporation (NYSE:BSX)2017 EPS Consensus Estimate: $1.26
2018 EPS Consensus Estimate: $1.40
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | $0.29 | $0.31 | $0.30 |
| Q2 2017 | 5 | $0.31 | $0.31 | $0.31 |
| Q3 2017 | 6 | $0.30 | $0.32 | $0.31 |
| Q4 2017 | 5 | $0.32 | $0.35 | $0.33 |
| Q1 2018 | 2 | $0.29 | $0.30 | $0.30 |
| Q2 2018 | 2 | $0.35 | $0.35 | $0.35 |
| Q3 2018 | 3 | $0.34 | $0.37 | $0.36 |
| Q4 2018 | 2 | $0.39 | $0.41 | $0.40 |
(Data provided by Zacks Investment Research)
Dividend History for Boston Scientific Corporation (NYSE:BSX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Boston Scientific Corporation (NYSE:BSX)Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 92.11%
Insider Trades by Quarter for Boston Scientific Corporation (NYSE:BSX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/11/2017 | Daniel J Brennan | CFO | Sell | 92,158 | $27.48 | $2,532,501.84 | |
| 7/3/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $27.87 | $278,700.00 | |
| 6/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $28.02 | $434,310.00 | |
| 6/9/2017 | David A Pierce | SVP | Sell | 13,562 | $28.00 | $379,736.00 | |
| 6/2/2017 | David A Pierce | SVP | Sell | 2,972 | $27.70 | $82,324.40 | |
| 6/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $27.13 | $271,300.00 | |
| 5/30/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $27.25 | $422,375.00 | |
| 5/17/2017 | Kevin J. Ballinger | EVP | Sell | 28,864 | $26.14 | $754,504.96 | |
| 5/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $26.37 | $263,700.00 | |
| 4/26/2017 | David A Pierce | SVP | Sell | 10,250 | $26.00 | $266,500.00 | |
| 4/26/2017 | Michael P. Phalen | EVP | Sell | 34,773 | $26.00 | $904,098.00 | |
| 4/10/2017 | John Bradley Sorenson | SVP | Sell | 2,950 | $24.66 | $72,747.00 | |
| 4/3/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $24.87 | $248,700.00 | |
| 3/29/2017 | Michael P. Phalen | EVP | Sell | 79,045 | $24.55 | $1,940,554.75 | |
| 3/3/2017 | David A Pierce | SVP | Sell | 25,012 | $25.01 | $625,550.12 | |
| 3/3/2017 | Timothy A Pratt | EVP | Sell | 23,540 | $25.01 | $588,735.40 | |
| 2/27/2017 | David A Pierce | SVP | Sell | 3,417 | $24.84 | $84,878.28 | |
| 2/27/2017 | Timothy A Pratt | EVP | Sell | 4,832 | $24.84 | $120,026.88 | |
| 2/7/2017 | Keith D Dawkins | EVP | Sell | 80,783 | $25.21 | $2,036,539.43 | |
| 1/9/2017 | David A Pierce | SVP | Sell | 10,232 | $22.24 | $227,559.68 | |
| 1/9/2017 | Timothy A Pratt | EVP | Sell | 6,195 | $22.24 | $137,776.80 | |
| 12/1/2016 | Timothy A Pratt | EVP | Sell | 26,726 | $20.48 | $547,348.48 | |
| 8/11/2016 | John Bradley Sorenson | SVP | Sell | 2,500 | $23.90 | $59,750.00 | |
| 8/1/2016 | Michael F Mahoney | CEO | Sell | 44,400 | $24.44 | $1,085,136.00 | |
| 8/1/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $24.46 | $587,040.00 | |
| 7/20/2016 | David A Pierce | SVP | Sell | 2,480 | $24.03 | $59,594.40 | |
| 7/20/2016 | Michael P. Phalen | EVP | Sell | 35,000 | $24.03 | $841,050.00 | |
| 6/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $22.69 | $2,269,000.00 | |
| 6/1/2016 | Timothy A Pratt | EVP | Sell | 24,229 | $22.66 | $549,029.14 | |
| 5/11/2016 | John Bradley Sorenson | SVP | Sell | 2,800 | $22.15 | $62,020.00 | |
| 5/10/2016 | Keith D Dawkins | EVP | Sell | 80,000 | $22.15 | $1,772,000.00 | |
| 5/6/2016 | Jeffrey B Mirviss | SVP | Sell | 24,659 | $21.94 | $541,018.46 | |
| 5/3/2016 | Joseph Michael Fitzgerald | EVP | Sell | 79,960 | $21.81 | $1,743,927.60 | |
| 5/2/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $22.12 | $2,212,000.00 | |
| 5/2/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $21.93 | $526,320.00 | |
| 4/27/2016 | Kevin J Ballinger | SVP | Sell | 111,807 | $21.62 | $2,417,267.34 | |
| 4/27/2016 | Timothy A Pratt | EVP | Sell | 39,927 | $21.40 | $854,437.80 | |
| 4/4/2016 | Jeffrey B Mirviss | SVP | Sell | 18,422 | $19.00 | $350,018.00 | |
| 4/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $18.90 | $1,890,000.00 | |
| 4/1/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $18.73 | $449,520.00 | |
| 3/11/2016 | Kevin J Ballinger | SVP | Sell | 16,705 | $18.00 | $300,690.00 | |
| 3/8/2016 | Karen Prange | SVP | Sell | 14,747 | $17.27 | $254,680.69 | |
| 3/2/2016 | Michael P. Phalen | EVP | Sell | 10,665 | $17.17 | $183,118.05 | |
| 3/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $16.96 | $1,696,000.00 | |
| 3/1/2016 | Timothy A Pratt | EVP | Sell | 15,068 | $16.97 | $255,703.96 | |
| 2/29/2016 | Kevin J. Ballinger | SVP | Sell | 2,114 | $17.17 | $36,297.38 | |
| 2/29/2016 | Michael P. Phalen | EVP | Sell | 1,819 | $17.19 | $31,268.61 | |
| 2/25/2016 | Daniel J Brennan | CFO | Sell | 103,211 | $17.22 | $1,777,293.42 | |
| 2/25/2016 | Kevin J. Ballinger | SVP | Sell | 1,903 | $17.48 | $33,264.44 | |
| 2/25/2016 | Michael P. Phalen | EVP | Sell | 34,106 | $17.28 | $589,351.68 | |
| 2/17/2016 | Kevin J. Ballinger | SVP | Sell | 7,616 | $17.37 | $132,289.92 | |
| 2/12/2016 | Charles J Dockendorff | Director | Buy | 30,000 | $16.49 | $494,700.00 | |
| 2/8/2016 | Karen Prange | SVP | Sell | 6,216 | $16.05 | $99,766.80 | |
| 1/8/2016 | Timothy A Pratt | EVP | Sell | 7,160 | $17.67 | $126,517.20 | |
| 1/7/2016 | Kevin J Ballinger | SVP | Sell | 19,059 | $17.73 | $337,916.07 | |
| 1/5/2016 | Jeffrey B Mirviss | SVP | Sell | 9,953 | $18.00 | $179,154.00 | |
| 12/1/2015 | Timothy A. Pratt | EVP | Sell | 24,000 | $18.43 | $442,320.00 | |
| 11/16/2015 | Ernest Mario | Director | Sell | 125,000 | $17.63 | $2,203,750.00 | |
| 11/9/2015 | John Bradley Sorenson | SVP | Sell | 4,469 | $18.68 | $83,480.92 | |
| 11/9/2015 | Joseph Michael Fitzgerald | EVP | Sell | 26,220 | $18.58 | $487,167.60 | |
| 11/5/2015 | Timothy A Pratt | EVP | Sell | 19,598 | $19.00 | $372,362.00 | |
| 10/28/2015 | Jeffrey B Mirviss | SVP | Sell | 9,492 | $18.00 | $170,856.00 | |
| 10/28/2015 | Timothy A Pratt | EVP | Sell | 3,500 | $18.00 | $63,000.00 | |
| 10/5/2015 | Timothy A Pratt | EVP | Sell | 3,500 | $17.34 | $60,690.00 | |
| 10/1/2015 | Timothy A. Pratt | EVP | Sell | 17,000 | $16.33 | $277,610.00 | |
| 8/21/2015 | John E Abele | Director | Buy | 200,000 | $16.77 | $3,354,000.00 | |
| 8/19/2015 | John E Abele | Director | Buy | 200,000 | $17.48 | $3,496,000.00 | |
| 8/17/2015 | John E Abele | Director | Buy | 100,000 | $17.50 | $1,750,000.00 | |
| 7/7/2015 | Karen Prange | SVP | Sell | 17,456 | $17.66 | $308,272.96 | |
| 5/29/2015 | Maulik Nanavaty | SVP | Sell | 71,558 | $18.52 | $1,325,254.16 | |
| 5/28/2015 | Wendy Carruthers | SVP | Sell | 42,281 | $17.91 | $757,252.71 | |
| 5/18/2015 | Ernest Mario | Director | Sell | 50,000 | $18.09 | $904,500.00 | |
| 5/14/2015 | John E Sununu | Director | Sell | 10,000 | $17.87 | $178,700.00 | |
| 5/11/2015 | John Bradley Sorenson | SVP | Sell | 8,735 | $17.49 | $152,775.15 | |
| 3/20/2015 | David A Pierce | SVP | Sell | 18,050 | $18.00 | $324,900.00 | |
| 3/20/2015 | Michael P Phalen | EVP | Sell | 46,085 | $17.94 | $826,764.90 | |
| 3/16/2015 | Michael P Phalen | EVP | Sell | 30,022 | $17.18 | $515,777.96 | |
| 3/13/2015 | John Bradley Sorenson | SVP | Sell | 3,830 | $16.84 | $64,497.20 | |
| 3/9/2015 | David A Pierce | SVP | Sell | 2,561 | $16.54 | $42,358.94 | |
| 3/3/2015 | David A Pierce | SVP | Sell | 8,983 | $16.79 | $150,824.57 | |
| 3/3/2015 | Michael P Phalen | EVP | Sell | 12,768 | $16.79 | $214,374.72 | |
| 2/27/2015 | David A Pierce | SVP | Sell | 19,046 | $16.80 | $319,972.80 | |
| 2/27/2015 | Michael P Phalen | EVP | Sell | 1,819 | $16.80 | $30,559.20 | |
| 2/19/2015 | David A Pierce | SVP | Sell | 11,958 | $16.46 | $196,828.68 | |
| 2/19/2015 | Michael P Phalen | EVP | Sell | 13,188 | $16.44 | $216,810.72 | |
| 2/10/2015 | Joseph Michael Fitzgerald | EVP | Sell | 61,208 | $14.66 | $897,309.28 | |
| 2/9/2015 | David A Pierce | SVP | Sell | 5,000 | $14.66 | $73,300.00 | |
| 2/6/2015 | Kevin J Ballinger | SVP | Sell | 21,408 | $15.06 | $322,404.48 | |
| 1/20/2015 | Michael P Phalen | EVP | Sell | 10,000 | $14.54 | $145,400.00 | |
| 1/8/2015 | David A Pierce | SVP | Sell | 18,612 | $14.31 | $266,337.72 | |
| 1/8/2015 | Michael P Phalen | EVP | Sell | 27,589 | $14.31 | $394,798.59 | |
| 1/5/2015 | Michael P Phalen | EVP | Sell | 10,000 | $13.75 | $137,500.00 | |
| 12/10/2014 | Karen Prange | SVP | Sell | 19,753 | $12.64 | $249,677.92 | |
| 12/8/2014 | David A Pierce | SVP | Sell | 5,000 | $12.90 | $64,500.00 | |
| 12/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.96 | $129,600.00 | |
| 11/28/2014 | Michael F Mahoney | CEO | Buy | 11,700 | $12.89 | $150,813.00 | |
| 11/10/2014 | Edward J Ludwig | Director | Buy | 10,000 | $13.38 | $133,800.00 | |
| 11/5/2014 | John E Sununu | Director | Sell | 8,997 | $13.38 | $120,379.86 | |
| 11/3/2014 | Ernest Mario | Director | Sell | 10,000 | $13.30 | $133,000.00 | |
| 10/8/2014 | Ernest Mario | Director | Sell | 10,000 | $12.06 | $120,600.00 | |
| 9/2/2014 | Ernest Mario | Director | Sell | 10,000 | $12.60 | $126,000.00 | |
| 8/15/2014 | Michael P Phalen | EVP | Sell | 11,471 | $12.58 | $144,305.18 | |
| 8/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.58 | $125,800.00 | |
| 7/30/2014 | David A Pierce | SVP | Sell | 157 | $12.97 | $2,036.29 | |
| 7/15/2014 | Michael P Phalen | EVP | Sell | 67,500 | $13.04 | $880,200.00 | |
| 7/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.95 | $129,500.00 | |
| 6/16/2014 | Michael P Phalen | EVP | Sell | 13,500 | $13.02 | $175,770.00 | |
| 6/2/2014 | Ernest Mario | Director | Sell | 10,000 | $12.88 | $128,800.00 | |
| 5/15/2014 | Michael Phalen | EVP | Sell | 13,500 | $12.76 | $172,260.00 | |
| 5/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.58 | $125,800.00 | |
| 4/15/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.25 | $178,875.00 | |
| 4/1/2014 | Ernest Mario | Director | Sell | 10,000 | $13.55 | $135,500.00 | |
| 3/17/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.05 | $176,175.00 | |
| 3/6/2014 | David Pierce | SVP | Sell | 5,316 | $13.44 | $71,447.04 | |
| 3/6/2014 | Michael Phalen | EVP | Sell | 7,281 | $13.44 | $97,856.64 | |
| 2/27/2014 | David Pierce | SVP | Sell | 2,057 | $13.29 | $27,337.53 | |
| 2/27/2014 | Michael Phalen | EVP | Sell | 3,166 | $13.29 | $42,076.14 | |
| 2/21/2014 | David Pierce | SVP | Sell | 3,199 | $13.22 | $42,290.78 | |
| 2/21/2014 | Michael Phalen | EVP | Sell | 3,222 | $13.22 | $42,594.84 | |
| 2/18/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.30 | $179,550.00 | |
| 2/13/2014 | Kristina Johnson | Director | Sell | 18,000 | $13.01 | $234,180.00 | |
| 2/6/2014 | Ernest Mario | Director | Sell | 17,104 | $12.80 | $218,931.20 | |
| 2/3/2014 | Ernest Mario | Director | Sell | 10,000 | $13.19 | $131,900.00 | |
| 1/6/2014 | Ernest Mario | Director | Sell | 10,000 | $12.50 | $125,000.00 | |
| 12/26/2013 | Ernest Mario | Director | Sell | 10,000 | $12.06 | $120,600.00 | |
| 11/26/2013 | Jeffrey Capello | CFO | Sell | 85,106 | $11.82 | $1,005,952.92 | |
| 11/11/2013 | Jeffrey Mirviss | SVP | Sell | 26,000 | $11.91 | $309,660.00 | |
| 8/29/2013 | Jeffrey Capello | CFO | Sell | 525,000 | $10.68 | $5,607,000.00 | |
| 8/16/2013 | Joseph Michael Fitzgerald | SVP | Sell | 9,202 | $11.02 | $101,406.04 | |
| 8/14/2013 | Kevin Ballinger | SVP | Sell | 38,171 | $11.28 | $430,568.88 | |
| 5/31/2013 | Jeffrey B Mirviss | SVP | Sell | 10,941 | $9.37 | $102,517.17 | |
| 5/30/2013 | Wendy Carruthers | SVP | Sell | 25,001 | $9.16 | $229,009.16 | |
| 5/29/2013 | Nelda J Connors | Director | Sell | 24,116 | $9.17 | $221,143.72 | |
| 5/6/2013 | Ernest Mario | Director | Buy | 30,000 | $7.76 | $232,800.00 | |
| 11/13/2012 | Nj Nicholas Jr | Director | Buy | 20,000 | $5.28 | $105,600.00 | |
| 11/9/2012 | Nj Nicholas Jr | Director | Buy | 25,000 | $5.17 | $129,250.00 | |
| 8/6/2012 | Ernest Mario | Director | Buy | 32,000 | $5.29 | $169,280.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Boston Scientific Corporation (NYSE:BSX)
Latest Headlines for Boston Scientific Corporation (NYSE:BSX)
| Source: |
|
| Date | Headline |
|---|
 | Boston Scientific Corp Q2 Income Advances 19% - Nasdaq
www.nasdaq.com - July 27 at 5:19 PM |
| Earnings Reaction History: Boston Scientific Corporation, 37.5 ... - Nasdaq
www.nasdaq.com - July 27 at 5:19 PM |
 | Boston Scientific tops Street 2Q forecasts
finance.yahoo.com - July 27 at 5:19 PM |
 | Boston Scientific Corporation (NYSE:BSX) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - July 27 at 4:59 PM |
| Analysts Expect Boston Scientific Corporation (NYSE:BSX) Will Post Quarterly Sales of $2.21 Billion
www.americanbankingnews.com - July 27 at 11:22 AM |
| Boston Scientific Corporation (NYSE:BSX) Issues Q3 Earnings Guidance
www.americanbankingnews.com - July 27 at 11:13 AM |
| Boston Scientific Corporation (BSX) Updates FY17 Earnings Guidance
www.americanbankingnews.com - July 27 at 11:12 AM |
 | Breakfast Technical Briefing on Medical Equipment Stocks -- Abbott ... - PR Newswire (press release)
www.prnewswire.com - July 26 at 5:22 PM |
| Zacks: Brokerages Anticipate Boston Scientific Corporation (NYSE:BSX) to Announce $0.31 EPS
www.americanbankingnews.com - July 26 at 12:28 AM |
| Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock? - Nasdaq
www.nasdaq.com - July 21 at 11:29 PM |
 | Boston Scientific joins in $36M round for Twin Cities med-tech startup
www.bizjournals.com - July 21 at 6:21 PM |
| Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock?
finance.yahoo.com - July 21 at 6:21 PM |
 | Abbott profit forecast gets a lift from St. Jude integration - Reuters
www.reuters.com - July 20 at 6:28 PM |
| Boston Scientific Corporation (BSX) Set to Announce Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:40 AM |
 | AxoGen, Inc. Appoints Jon Gingrich Chief Commercial Officer
feeds.benzinga.com - July 17 at 7:31 AM |
| FDA's 60-Day Extension For Medical Device Defects Not Likely Obstructive To Public Health - Benzinga
www.benzinga.com - July 14 at 11:43 PM |
| Boston Scientific Corporation (BSX) CFO Sells $2,532,501.84 in Stock
www.americanbankingnews.com - July 12 at 7:53 PM |
 | 3 Red-Hot Medical Tech Stocks That Could Beat Earnings Estimates - 24/7 Wall St.
247wallst.com - July 11 at 5:46 PM |
| Boston Scientific Corporation (BSX) Downgraded to Buy at BidaskClub
www.americanbankingnews.com - July 8 at 1:02 PM |
 | Class Action Regarding Boston Scientific Transvaginal Mesh Devices Has Been Certified
www.marketwatch.com - July 8 at 9:28 AM |
| Boston Scientific to Webcast Conference Call Discussing Second Quarter 2017 ...
www.prnewswire.com - July 6 at 6:00 PM |
| Timothy A. Pratt Sells 10,000 Shares of Boston Scientific Corporation (NYSE:BSX) Stock
www.americanbankingnews.com - July 5 at 7:26 PM |
| Boston Scientific to Webcast Conference Call Discussing Second Quarter 2017 Financial Results
finance.yahoo.com - July 5 at 5:32 PM |
| Eastman Chemical Achieves #89 Analyst Rank, Surpassing Boston Scientific
www.nasdaq.com - July 3 at 4:49 PM |
| How Has Boston Scientific Stock Performed Recently?
finance.yahoo.com - July 3 at 4:49 PM |
| Boston Scientific Corporation (BSX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 3 at 12:56 PM |
| Boston Scientific Corporation (BSX) PT Raised to $31.00 at Barclays PLC
www.americanbankingnews.com - July 2 at 12:38 PM |
| Boston Scientific Corporation (NYSE:BSX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 2 at 12:02 PM |
| Boston Scientific Corporation (BSX) Expected to Announce Quarterly Sales of $2.21 Billion
www.americanbankingnews.com - July 1 at 8:16 AM |
| What Analysts Recommend for Boston Scientific
finance.yahoo.com - June 30 at 4:51 PM |
| How Boston Scientific’s Alair System Performed in Trials
finance.yahoo.com - June 30 at 4:51 PM |
| ETFs with exposure to Boston Scientific Corp. : June 30, 2017
finance.yahoo.com - June 30 at 4:50 PM |
| Boston Scientific Corporation (BSX) to Post FY2019 Earnings of $1.51 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - June 30 at 12:25 PM |
| Equities Analysts Issue Forecasts for Boston Scientific Corporation's Q3 2018 Earnings (BSX)
www.americanbankingnews.com - June 30 at 11:20 AM |
| Brokerages Anticipate Boston Scientific Corporation (BSX) to Post $0.31 Earnings Per Share
www.americanbankingnews.com - June 29 at 8:32 PM |
| Boston Scientific Corporation (BSX) EVP Sells $434,310.00 in Stock
www.americanbankingnews.com - June 29 at 7:49 PM |
| Featured Company News - Boston Scientific Outlined Sustained Growth Strategy; Set to Expand into New Markets and Product Portfolios
finance.yahoo.com - June 29 at 5:58 PM |
| Zacks Investment Research Lowers Boston Scientific Corporation (BSX) to Hold
www.americanbankingnews.com - June 29 at 11:54 AM |
| Q1 2018 EPS Estimates for Boston Scientific Corporation (BSX) Lowered by Leerink Swann
www.americanbankingnews.com - June 29 at 10:32 AM |
| Boston Scientific Corporation to Post Q4 2017 Earnings of $0.34 Per Share, Jefferies Group Forecasts (BSX)
www.americanbankingnews.com - June 29 at 10:08 AM |
| SunTrust Banks Equities Analysts Increase Earnings Estimates for Boston Scientific Corporation (BSX)
www.americanbankingnews.com - June 29 at 8:16 AM |
| Boston Scientific Corporation's (BSX) Hold Rating Reiterated at Oppenheimer Holdings Inc.
www.americanbankingnews.com - June 28 at 11:40 PM |
| Boston Scientific Corporation's (BSX) "Overweight" Rating Reiterated at J P Morgan Chase & Co
www.americanbankingnews.com - June 28 at 9:52 PM |
| 5 Biggest Price Target Changes For Wednesday - Benzinga
www.benzinga.com - June 28 at 9:49 PM |
| Boston Scientific Corporation's (BSX) "Hold" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - June 28 at 2:32 PM |
| Jefferies Group LLC Reiterates "Hold" Rating for Boston Scientific Corporation (BSX)
www.americanbankingnews.com - June 28 at 2:32 PM |
| SunTrust Banks Weighs in on Boston Scientific Corporation's FY2019 Earnings (BSX)
www.americanbankingnews.com - June 28 at 2:06 PM |
| Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day
finance.yahoo.com - June 27 at 4:18 PM |
| Boston Scientific Corporation's (BSX) "Neutral" Rating Reaffirmed at BTIG Research
www.americanbankingnews.com - June 27 at 11:34 AM |
 | Boston Scientific hosts Investor Day today; goal of 6-8% organic annual revenue growth and double-digit annual non-GAAP EPS growth next three years; shares up 1%
seekingalpha.com - June 27 at 10:47 AM |
Boston Scientific Corporation (BSX) Chart for Thursday, July, 27, 2017
